朗生醫藥(00503.HK)累計出售972.9萬股司太立(603520.SH)股份
格隆匯12月12日丨朗生醫藥(00503.HK)公佈,於2019年12月9日至2019年12月12日期間,根據司太立出售授權及第五次股份減持計劃,公司以平均每股人民幣39.63元的價格在市場出售合共167.89萬股司太立(603520.SH)股份,扣除交易成本及相關税款前的出售所得款項總額約為人民幣6654萬元。由於該出售,集團預計能獲得約646萬美元的淨收益。
公司自獲得司太立出售授權之日起合共出售了972.90萬股司太立股份。此次出售後,集團仍持有671.60萬股司太立股份。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.